Biomarkers for diagnosing alzheimer's disease
View Patent ↗A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific peptide markers, e.g., using mass spectrometric analysis.
1. A method for assessing the state of Alzheimer's disease in a subject, wherein the method comprises detecting in a sample from the subject at least five distinct polypeptides meeting the following criteria:
a first polypeptide having the amino acid sequence of SEQ ID NO: 17;
a second polypeptide having the amino acid sequence of SEQ ID NO: 1 or 2;
a third polypeptide having the amino acid sequence of SEQ ID NO: 3;
a fourth polypeptide having the amino acid sequence of SEQ ID NO: 4, 5, or 6; and
a fifth polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 7 to SEQ ID NO: 16.
2. The method of claim 1 , wherein the method further comprises contacting the sample with an antibody that specifically binds to one of the at least five polypeptides.
3. The method of claim 1 , wherein one or more of the at least five polypeptides is detected by SELDI-TOF MS.
4. The method of claim 1 , wherein the method is performed on at least two samples from the subject.
5. The method of claim 1 , wherein the sample is CSF, blood, serum, plasma, urine, seminal plasma, nipple fluid, or cell extract.